Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Investing

Colgate-Palmolive stock analysis: overvalued ahead of earnings

admin by admin
January 30, 2025
in Investing
0
Colgate-Palmolive stock analysis: overvalued ahead of earnings
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

The Colgate-Palmolive stock price remains in a deep correction as investors wait for the fourth-quarter results. CL has plunged by over 17%, bringing its market cap to about $73 billion. So, is Colgate a good stock to buy the dip in?

Colgate-Palmolive is a good value company

Colgate-Palmolive is a leading company in the consumer staples industry. The firm operates its business in two key segments: oral, personal, and home care, and pet nutrition. It is one of the biggest players in the industry, owning brands like Colgate, Sorriso, Tom’s of Maine, and Sanex. 

Colgate-Palmolive’s business has done well in the past few years as its annual revenue rose from $15.7 billion in 2019 to over $20 billion in the trailing twelve months (TTM). The net income has moved from $2.16 billion in 2021 to over $2.86 billion.

The next key catalyst for the Colgate-Palmolive stock will be its upcoming financial results, which will come out on Friday. Analysts anticipate that the company’s revenue will come in at $5 billion, a 0.78% increase from the same period a year ago.

Colgate-Palmolive’s annual revenue will come in at $20.15 billion, a 3.52% annual increase. Its 2025 revenue guidance will be $20.39 billion, a 1.27% annual increase. 

These numbers mean that Colgate’s growth has largely stalled and is underperforming other companies. As such, it has become highly overvalued, with a forward P/E ratio of 25.45, up from the sector median of 18.5. The trailing-twelve-month P/E ratio of 25.8 is also higher than the sector median of 21. 

Still, analysts are optimistic that its stock wil rebound in the future. The Colgate stock forecast is $100, up from the current $89.57. The most notable bullish analysts are RBC Capital, Stifel, and UBS. 

Read more: Colgate-Palmolive (CL): dividend king stock gets overbought

Colgate-Palmolive stock price analysis

CL stock price chart by TradingView

The weekly chart shows that the CL share price peaked at $108.25 in 2024 and has now dropped to $85.80, its lowest point in April last year. 

It has stalled at the 38.2% Fibonacci Retracement point. It has moved between the 50-week and 100-week moving averages. It is hovering at the strong pivot reverse point of the Murrey Math Lines tool.

Therefore, the Colgate-Palmolive stock price will likely drop after earnings. If this happens, the next point to watch will be the 50% retracement level at $78.20 or 12% below the current level. This is an important level since it was also the highest point in 2020, 2021, 2022, and 2023. This view will be confirmed if drops below the support at $85.80. 

On the flip side, a move above the 23.60% retracement point at $94.40 will invalidate the bearish view.

The post Colgate-Palmolive stock analysis: overvalued ahead of earnings appeared first on Invezz

Previous Post

Apple Q1 earnings preview: China market share, AI strategy and other things to look out for

Next Post

How billionaire Caltagirone could influence Italy’s banking M&A wave

admin

admin

Next Post
How billionaire Caltagirone could influence Italy’s banking M&A wave

How billionaire Caltagirone could influence Italy’s banking M&A wave

Trending News

FTSE 100 and FTSE 250 shares to watch: Debenhams, Asos, Unilever, St. James Place

FTSE 100 and FTSE 250 shares to watch: Debenhams, Asos, Unilever, St. James Place

April 18, 2025
Elf Beauty bets big on rural market with Dollar General partnership

Elf Beauty bets big on rural market with Dollar General partnership

November 7, 2024
Broadcom stock has turned $1,000 into $9,000 in 4 years: what’s next?

Broadcom stock has turned $1,000 into $9,000 in 4 years: what’s next?

September 30, 2024
Subscribe to Insightful Word


    Recent News

    Archer Aviation wins LA28 Olympics contract: is ACHR grossly undervalued?

    Archer Aviation wins LA28 Olympics contract: is ACHR grossly undervalued?

    May 17, 2025
    Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

    Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

    May 17, 2025
    What made Cox Communications say ‘yes’ to a buyout after years of resistance?

    What made Cox Communications say ‘yes’ to a buyout after years of resistance?

    May 17, 2025
    Charter, Cox to merge in mega deal to counter streaming and wireless giants

    Charter, Cox to merge in mega deal to counter streaming and wireless giants

    May 17, 2025

    Recent News

    Archer Aviation wins LA28 Olympics contract: is ACHR grossly undervalued?

    Archer Aviation wins LA28 Olympics contract: is ACHR grossly undervalued?

    May 17, 2025
    Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

    Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

    May 17, 2025

    Latest News

    • Archer Aviation wins LA28 Olympics contract: is ACHR grossly undervalued?
    • Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in
    • What made Cox Communications say ‘yes’ to a buyout after years of resistance?

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.